These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 16614237

  • 41. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
    Vansteenkiste J, Poulsen E, Rossi G, Glaspy J.
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):45-55. PubMed ID: 12435173
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia.
    Blumer J, Berg S, Adamson PC, Loew T, Rossi G, Hastings C.
    Pediatr Blood Cancer; 2007 Oct 15; 49(5):687-93. PubMed ID: 17120240
    [Abstract] [Full Text] [Related]

  • 47. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH, Holzer H, Mayer GJ, Osterreichische Aranesp Studiengruppe.
    Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):967-71. PubMed ID: 12635463
    [Abstract] [Full Text] [Related]

  • 48. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP, Xie J, Williams D, Woodman RC, Wilhelm FE.
    Support Care Cancer; 2007 Dec 30; 15(12):1385-92. PubMed ID: 17541653
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct 30; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
    Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, Schuette W.
    Clin Lung Cancer; 2011 Jan 30; 12(1):62-9. PubMed ID: 21273182
    [Abstract] [Full Text] [Related]

  • 53. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Jan 30; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 54. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
    Glaspy JA, Charu V, Luo D, Moyo V, Kamin M, Wilhelm FE.
    Cancer; 2009 Mar 01; 115(5):1121-31. PubMed ID: 19170225
    [Abstract] [Full Text] [Related]

  • 55. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.
    Clin Ther; 2003 Nov 01; 25(11):2781-96. PubMed ID: 14693304
    [Abstract] [Full Text] [Related]

  • 56. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA.
    Curr Med Res Opin; 2011 May 01; 27(5):951-60. PubMed ID: 21381892
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr 01; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

  • 59. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL, Falk RJ.
    Pharmacotherapy; 2007 May 01; 27(5):734-44. PubMed ID: 17461709
    [Abstract] [Full Text] [Related]

  • 60. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan 01; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.